Literature DB >> 19789041

Completion pancreatectomy and duodenectomy for recurrent MEN-1 pancreaticoduodenal endocrine neoplasms.

Paul G Gauger1, Gerard M Doherty, James T Broome, Barbra S Miller, Norman W Thompson.   

Abstract

BACKGROUND: The purpose of this study is to describe outcomes of MEN-1 patients with recurrence requiring completion pancreatectomy and duodenectomy after initial treatment of pancreatic endocrine neoplasms (PENs) and hypergastrinemia with distal pancreatectomy, enucleation of pancreatic head PENs, and duodenotomy.
METHODS: After undergoing this initial operation, 8 of 49 patients (16%) have required completion pancreatectomy and duodenectomy for recurrent PENs and hypergastrinemia. Retrospective review was performed.
RESULTS: Median age was 39 years (27-51) at completion pancreatectomy compared to 31 years (20-40) at initial operation. Pathology revealed multiple PENs in 100%, duodenal neoplasms in 63%, and metastatic lymph nodes in 75%. There was no operative mortality and 88% of patients are currently alive. Preoperative gastrin levels were 934 +/- 847 pg/mL while postoperative levels are 93 +/- 79 pg/mL (normal 25-111 pg/mL). Mean Hemoglobin A1C levels are 8.3 +/- 3.3% (normal 3.8%-6.4%). Mean follow-up is 44 +/- 25 months.
CONCLUSION: This initial operation may provide tumor control and prevent metastases but recurrent PENs are multifocal and progressive. Completion pancreatectomy and duodenectomy is arduous but outcomes are acceptable. Considering the radical nature of this treatment, individual consideration should be given to MEN-1 patients amenable to initial alternative pancreatic resections that preserve pancreatic mass and allow future pancreas-preserving reoperations.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19789041     DOI: 10.1016/j.surg.2009.06.038

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  7 in total

Review 1.  [Neuroendocrine tumors of the duodenum and pancreas. Surgical strategy].

Authors:  L Fischer; A Mehrabi; M W Büchler
Journal:  Chirurg       Date:  2011-07       Impact factor: 0.955

2.  [Surgery for neuroendocrine tumors of the gastroenteropancreatic system (GEP-NET)].

Authors:  P E Goretzki; A Starke; A Akca; B J Lammers
Journal:  Internist (Berl)       Date:  2012-02       Impact factor: 0.743

3.  Long-term results of surgery for pancreatic neuroendocrine neoplasms in patients with MEN1.

Authors:  Caroline L Lopez; Jens Waldmann; Volker Fendrich; Peter Langer; Peter H Kann; Detlef K Bartsch
Journal:  Langenbecks Arch Surg       Date:  2011-07-30       Impact factor: 3.445

Review 4.  Care for patients with multiple endocrine neoplasia type 1: the current evidence base.

Authors:  C R C Pieterman; M R Vriens; K M A Dreijerink; R B van der Luijt; G D Valk
Journal:  Fam Cancer       Date:  2011-03       Impact factor: 2.375

5.  Pancreaticoduodenectomy Is the Best Surgical Procedure for Zollinger-Ellison Syndrome Associated with Multiple Endocrine Neoplasia Type 1.

Authors:  Weihua Kong; Max Benjamin Albers; Jerena Manoharan; Joachim Nils Goebel; Peter Herbert Kann; Moritz Jesinghaus; Detlef Klaus Bartsch
Journal:  Cancers (Basel)       Date:  2022-04-11       Impact factor: 6.575

6.  Long-term Follow-up of MEN1 Patients Who Do Not Have Initial Surgery for Small ≤2 cm Nonfunctioning Pancreatic Neuroendocrine Tumors, an AFCE and GTE Study: Association Francophone de Chirurgie Endocrinienne & Groupe d'Etude des Tumeurs Endocrines.

Authors:  Frederic Triponez; Samira M Sadowski; François Pattou; Catherine Cardot-Bauters; Eric Mirallié; Maëlle Le Bras; Frédéric Sebag; Patricia Niccoli; Sophie Deguelte; Guillaume Cadiot; Gilles Poncet; Jean-Christophe Lifante; Françoise Borson-Chazot; Philippe Chaffanjon; Olivier Chabre; Fabrice Menegaux; Eric Baudin; Philippe Ruszniewski; Hélène Du Boullay; Pierre Goudet
Journal:  Ann Surg       Date:  2018-07       Impact factor: 12.969

Review 7.  Surgical management of pancreatico-duodenal tumors in multiple endocrine neoplasia syndrome type 1.

Authors:  Göran Akerström; Peter Stålberg; Per Hellman
Journal:  Clinics (Sao Paulo)       Date:  2012       Impact factor: 2.365

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.